ANIK

Business Context and Reporting Period

Company: Anika Therapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1999
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for bone, cartilage, and soft tissue repair. Key products include ORTHOVISC (human osteoarthritis), HYVISC (equine osteoarthritis), and AMVISC (ophthalmic surgery viscoelastic supplements manufactured for Bausch & Lomb). ORTHOVISC is marketed internationally but remains in Phase III clinical trials in the U.S.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Product revenue increased 9.5% in the quarter and 15.8% year-to-date (YTD) compared to 1998. However, total revenue YTD decreased slightly due to the absence of $1.5 million in licensing payments received in the prior year.
• Profitability: Net income dropped significantly to $755,833 YTD from $3.58 million in the prior year. The company reported a near-break-even net income of $4,186 for the quarter.
• Expenses: Research and Development (R&D) expenses surged 141% YTD to $2.83 million, driven by the initiation of the ORTHOVISC Phase III clinical trial. Selling, General, and Administrative (SG&A) expenses increased 7.4% YTD.
• Margins: Gross margin declined from 52.0% to 48.1% YTD due to an unfavorable product mix (lower margin AMVISC sales vs. higher margin ORTHOVISC) and increased manufacturing overhead.
• Liquidity: Cash and cash equivalents decreased by $9.3 million YTD, primarily due to investments in long-term securities ($5.6 million), capital expenditures ($1.4 million), and stock repurchases ($1.9 million).

Guidance, Outlook, and Risks

• Clinical Trials: The company is conducting a Phase III clinical trial for ORTHOVISC in the U.S. and Canada, having incurred approximately $1.4 million in 1999. An additional $1.3 million is expected to complete the trial over the next three quarters.
• Manufacturing: Capital expenditures of $1.4 million were made to expand capacity, with an additional $580,000 expected in late 1999. Capacity is projected to meet demand through 2003.
• Key Risks:
  • Regulatory Approval: No assurance that the FDA will approve the PMA for ORTHOVISC. The previous application was rejected in 1998, requiring additional clinical data.
  • Customer Concentration: Bausch & Lomb Surgical accounted for 61.8% of product revenue YTD. The contract contains minimum purchase obligations; failure to meet these could lead to termination.
  • Distributor Risk: Zimmer, Inc. (distributor for ORTHOVISC) has missed minimum sales targets for 1998 and is expected to miss them for 1999. This creates a risk of contract termination or reduced future orders.
  • Profitability: Despite recent profitability, the company has an accumulated deficit of $924,579. Future profitability is uncertain and dependent on regulatory approvals and market acceptance.
• Stock Repurchase: The company repurchased 402,600 shares in 1999 under a $4 million authorization plan.

Investor Verification Checklist

• Verify the status and preliminary results of the ORTHOVISC Phase III clinical trial and the timeline for FDA PMA submission.
• Confirm the stability of the supply agreement with Bausch & Lomb Surgical and whether minimum purchase obligations are being met.
• Assess the risk of contract termination with Zimmer, Inc., given their failure to meet sales minimums for two consecutive years.
• Review the company's cash burn rate relative to its $20.6 million in liquid assets to confirm the 24-month runway estimate.
• Monitor the outcome of the patent interference proceeding regarding the INCERT product.